Media Kit. September 2017
|
|
- Geraldine Daniela Park
- 6 years ago
- Views:
Transcription
1 Media Kit September 2017
2 About Pear Pear Therapeutics is the leader in FDA-cleared Prescription Digital Therapeutics. The company s approach is to integrate clinically-validated software applications with previously approved pharmaceuticals and treatment paradigms to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear s lead product, reset, is an FDA-cleared 12-week interval prescription therapy for Substance Use Disorder (SUD) to be used as an adjunct to standard, outpatient treatment. Pear s product development pipeline includes reset-o for opioid use disorder (OUD) and additional prescription digital therapeutics in schizophrenia (Thrive ), combat post traumatic stress disorder (recall ), general anxiety disorder (revive ), pain, major depressive disorder, and insomnia, for which Pear intends to obtain FDA clearance. Launched in 2013 Based in Boston and San Francisco First, and only, FDA-cleared prescription digital therapeutic with claims to improve patient outcomes Pear is committed to bettering patient outcomes through technology
3 Corporate Timeline Milestone Screens 2,500 digital technologies Pear Therapeutics is formed Forms Advisory Board chaired by Patrick Kennedy Seed financing from Kennedy Family Foundation and 5AM Ventures In-licenses TES from Dartmouth University Raises $20M financing FDA submission for reset Launch reset pilot studies Receives NIDA grant 17 patents issued Receives FDA-clearance for reset reset launch AUG 2013 OCT 2013 NOV 2013 MAR 2015 JUL 2015 FEB 2016 MAY 2016 DEC 2016 JUL 2017 SEP 2017 SEP
4 About Prescription Digital Therapeutics Prescription Digital Therapeutics are clinicallyvalidated, FDA-cleared software applications that demonstrate safety and efficacy in randomized clinical trials to improve patient outcomes. Prescription Digital Therapeutics are designed to enhance clinical outcomes, and where clinically relevant, may be combined with current treatment regimens including approved drug or device therapies and patient counseling. Prescription Digital Therapeutics usually include patient-facing applications, clinical assessment and outcomes tracking, clinician monitoring dashboards and HIPAA-compliant data storage.
5 FDA s Digital Health Initiative Links to latest FDA correspondence concerning digital health: Digital Health Software Precertification (PreCert) Program Fostering Medical Innovation: A Plan for Digital Health Devices FDA Announces New Steps to Empower Consumers and Advance Digital Healthcare
6 About reset reset is a 12-week (90 day), FDA-cleared prescription digital therapeutic to be used as an adjuvant to standard outpatient therapy for treating Substance Use Disorder (SUD) related to stimulants, cannabis, cocaine and alcohol. The product combines patient-facing interventions and assessments via a mobile device, with clinician-facing dashboards and data analytics on the back-end. reset has been proven to increase abstinence from a patient s substances of abuse during treatment and retention in the outpatient treatment program. reset provides clinicians with immediate access to self-reported substance use, triggers, cravings and outcomes. reset is limited to persons with a valid prescription from their licensed provider and is intended is for patients 18 years of age and older.
7 How reset Works reset is a prescription digital therapeutic designed and engineered to deliver neurobehavioral therapy modeled on the Community Reinforcement Approach (CRA) for patients with Substance Use Disorder (SUD). CRA is a specific form of cognitive behavioral therapy (CBT) designed for patients with SUD. reset combines CRA (for therapy) and fluency learning (to reinforce concept mastery) and can be implemented in conjunction with Contingency Management to support and incentivize patients with SUD in achieving abstinence and retention in outpatient SUD treatment. Patients are able to download the application on their mobile device. Following the download, patients can activate the product with a prescription access code provided by their physician or medical provider. Access codes correspond to the duration of the FDA-cleared label (and clinical study), in the case of reset stipulating 12 weeks of therapy. The patient s physicians or medical providers can monitor the patient s treatment and progress from a clinician dashboard as they progress through various modules and responses to questions.
8 About reset
9 About reset
10 About Substance Use Disorder In 2016, approximately 20.1 million people aged 12 or older had a substance use disorder (SUD) related to their use of alcohol or illicit drugs in the past year. Abuse of and addiction to alcohol, nicotine, and illicit and prescription drugs cost Americans more than $700 billion a year in increased health care costs, crime and lost productivity, and contribute to the death of more than 90,000 Americans. According to the Substance Abuse and Mental Health Services Administration (SAMHSA), only about 1 in 10 people who needed substance use treatment received treatment at a specialty facility in the past year (10.6 percent). Link to SAMHSA Report
11 Leadership Corey McCann, M.D., Ph.D. Founder and Chief Executive Officer Boston, MA San Francisco, CA Dr. McCann is a physician, scientist, entrepreneur, and healthcare investor. Previously, he was an investor with MPM Capital and with RiverVest Venture Partners, where he evaluated new investment opportunities, managed relationships with strategic partners, and oversaw board-level strategy and execution at portfolio companies. Prior to MPM, he was with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. He also led McKinsey s Central Nervous System (CNS) expertise group, serving clients across pharma and biotech. He is a founding member of multiple start-ups including Alcyone Lifesciences, a company developing technologies to deliver therapeutics to the brain. Additionally, he is a co-founder, advisor or Board Director for multiple start-ups, including at AgNovos Healthcare, Alcyone Lifesciences, Dragonfly Sciences, Edumedics, New Frontier Bio, Resolute Bio, Selexys Pharmaceuticals and Zillion Health. Dr. McCann s post-graduate training was at Harvard University, Washington University in St Louis, and at the Massachusetts General Hospital, and he graduated summa cum laude from The Pennsylvania State University where he was an Evan Pugh Scholar.
12 Pipeline Pear s robust pipeline includes the reset and reset-o programs, as well as further product development programs in additional CNS disorders.
13 Contacts Pear Therapeutics: Media: MacDougall Biomedical Communications Karen Sharma or Stefanie Tuck (781)
Evidence-Based Digital Therapies for Enhanced Clinical Outcomes
COREY MCCANN, MD, PHD Founder and CEO Pear Therapeutics Evidence-Based Digital Therapies for Enhanced Clinical Outcomes How Self-Care Technology Is Changing Lives and Improving Treatment Speaker Name Title
More informationTreatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This fact sheet discusses research findings on effective treatment approaches for drug abuse and addiction. If you re seeking treatment, you can call the Substance
More informationBrain Resource. For personal use only. riding the wave of demand for brain health solutions
Brain Resource riding the wave of demand for brain health solutions Dan Segal, COO dans@brainresource.com Sydney and San Francisco May 2011 1 10 year track record Founded 2001, international research consortium
More informationApplying Mobile Technology to Mental Health and Substance Use Disorders: The State of the Science
Applying Mobile Technology to Mental Health and Substance Use Disorders: The State of the Science Lisa A. Marsch, PhD Director, Dartmouth Center for Technology and Behavioral Health Director, Northeast
More informationIMPLEMENTING RECOVERY ORIENTED CLINICAL SERVICES IN OPIOID TREATMENT PROGRAMS PILOT UPDATE. A Clinical Quality Improvement Program
IMPLEMENTING RECOVERY ORIENTED CLINICAL SERVICES IN OPIOID TREATMENT PROGRAMS PILOT UPDATE A Clinical Quality Improvement Program Today: National completion rates for OTP s hover between 11 14% Retention
More informationEvaluation of National Academic Detailing Service on Naloxone Kit Prescription Rates in the Veterans Health Administration
Evaluation of National Academic Detailing Service on Naloxone Kit Prescription Rates in the Veterans Health Administration Melissa LD Christopher, PharmD National Director Academic Detailing Program Office
More informationTouchpoints Prior to Opioid Overdose Death
Touchpoints Prior to Opioid Overdose Death 7th Annual BU-CTSI Translational Science Symposium May 3, 2018 Marc Larochelle, MD, MPH Assistant Professor of Medicine Boston Medical Center and Boston University
More informationSubmitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis
STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More informationCompleting the Circle: Novel Methods for using PRO Scores in Shared Decision- Making and Patient Self-Management.
Completing the Circle: Novel Methods for using PRO Scores in Shared Decision- Making and Patient Self-Management. Karon Cook, PhD, Northwestern University Chicago, IL Thursday, September 28, 2017 Relevant
More informationHow Technology Is Shaping Addiction Treatment: Remote Monitoring, Mobile Apps, & More
How Technology Is Shaping Addiction Treatment: Remote Monitoring, Mobile Apps, & More #OMTechnology Wednesday, November 8, 2017 ⅼ 9:45 am 11:00 am Matt Chamberlain, Senior Associate, OPEN MINDS 1 www.openminds.com
More informationQUARTERLY PROVIDER MEETING MARCH 9, 2017 SUZANNE BORYS, ED.D.
2017 State Targeted Response to the Opioid Crisis Grants QUARTERLY PROVIDER MEETING MARCH 9, 2017 SUZANNE BORYS, ED.D. H.R.6-21st Century Cures Act The 21st Century Cures Act is a United States law enacted
More informationAvenue Therapeutics, Inc. September 2016
Avenue Therapeutics, Inc. September 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the
More informationAvenue Therapeutics, Inc. May 2017
Avenue Therapeutics, Inc. May 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationSTRENGTHENING THE COORDINATION, DELIVERY AND MONITORING OF HIV AND AIDS SERVICES IN MALAWI THROUGH FAITH-BASED INSTITUTIONS.
STRENGTHENING THE COORDINATION, DELIVERY AND MONITORING OF HIV AND AIDS SERVICES IN MALAWI THROUGH FAITH-BASED INSTITUTIONS. Acknowledgements This project was fully funded by Center For Disease Control
More informationPublication Plan 2017
Publication Plan 2017 A passion for turning high quality, independent research insights into actionable commercial intelligence. Why Spherix Global Insights? Our independent reports are designed, developed,
More informationONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE AT KANTAR HEALTH, ONCOLOGY
More informationAvenue Therapeutics, Inc. August 2016
Avenue Therapeutics, Inc. August 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationCastle Creek Pharmaceuticals
Castle Creek Pharmaceuticals Dermatology Summit Entrepreneurial Showcase 2018 Michael Derby, CEO January 7, 2018 Castle Creek Pharma Driving innovation in dermatology We are a high-growth biotech company
More informationImproving Opioid Agonist Therapies with System Change
Improving Opioid Agonist Therapies with System Change DENNIS MCCARTY OHSU- PSU SCHOOL OF PUBLIC HEALTH OREGON HEALTH & SCIENCE UNIVERSITY PORTLAND, OR 97239 BOOST LAUNCH VANCOUVER, BC SEPTEMBER 15, 2017
More informationThe Opioid Addiction Emergency In Virginia June 8, 2017
The Opioid Addiction Emergency In Virginia June 8, 2017 Marissa J. Levine, MD MPH State Health Commissioner Virginia Department of Health Chronic Disease of Addiction Definition: A primary, chronic disease
More informationQ3 18 Earnings Supplemental Slides
(Nasdaq: INSY) Q3 18 Earnings Supplemental Slides November 5, 2018 Safe-Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements
More informationTreatment Team Approaches in Substance Abuse Treatment
Treatment Team Approaches in Substance Abuse Treatment PLANT A SEED AND WATCH IT GROW 2 Substance use disorders span a wide variety of problems arising from substance use, and cover 11 different criteria:
More informationWatson Summit Prague 2017
Watson for Oncology Matěj Adam Watson Health Executive May 2017 Watson Summit Prague 2017 an IBM Company Leadership & 23 Years Patent Leadership Research Spend Global Presence Technology 7300+ 2015 $6B
More informationEffective Management of Substance Use Disorder Patients in an Emergency Department Setting
Effective Management of Substance Use Disorder Patients in an Emergency Department Setting Les Sperling, CKF Chief Executive Officer Kim Spencer, CKF Program Director of Medical Services Angela Gamber,
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Shire plc January 10, 2012 Angus Russell Chief Executive Officer Our purpose We enable people with life-altering conditions to lead better lives. THE SAFE HARBOR STATEMENT
More informationSPECIALTY MEDICAL CANNABIS COMPANY
SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward
More informationH. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review
H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review BioPortfolio has been marketing business and market research reports
More informationNCACH RAPID CYCLE APPLICATION: OPIOID PROJECT North Central Accountable Community of Health - Medicaid Transformation Project
NCACH RAPID CYCLE APPLICATION: OPIOID PROJECT North Central Accountable Community of Health - Introduction The North Central Accountable Community of Health (NCACH) is accepting applications from partners
More informationDIRECT SPINAL THERAPEUTICS INC.
DIRECT SPINAL THERAPEUTICS INC. Novel Spinal Cord Modulation Platform Overview Presentation May 2014 Direct Spinal Therapeutics Inc. (DSTI) Proprietary Neuromodulation product/platform originated at Univ.
More informationInvestor Presentation May 2, 2017
CSE: TBP OTC: GRPOF Investor Presentation May 2, 2017 Forward Looking Statements This presentation contains certain forward-looking statements that may involve a number of risks and uncertainties. Actual
More informationCEO Operational Report. Annual General Meeting 23 October 2013
CEO Operational Report Annual General Meeting 23 October 2013 Leading the Field Clinical Trials Axon Sports Cogstate Research COGNIGRAM Playing an integral role in cognition-related clinical trials Cutting
More informationOWC PHARMACEUTICALS RESEARCH OTCQB:OWCP
OWC PHARMACEUTICALS RESEARCH OTCQB:OWCP Disclaimer This document details business information of OWC Pharmaceuticals Research Corp and/or our wholly-owned Israeli subsidiary, One World Cannabis Ltd. (collectively,
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationIntroducing A New Platform In Cancer Care Robotically Assisted Sonic Therapy (RAST)
Introducing A New Platform In Cancer Care Robotically Assisted Sonic Therapy (RAST) CED Life Science Conference February 27, 2018 Almost 40% of us will be diagnosed with cancer at some point in our lives
More informationAnnual General Meeting
Annual General Meeting November 2017 ASX: MEB OTCQB: MDBIF Medibio Limited 2016 2 DISCLAIMER FORWARD LOOKING STATEMENTS Accordingly, these slides and the information they contain should be read in conjunction
More informationAXIM Biotechnologies Reports Year End 2017 Results
March 19, 2018 AXIM Biotechnologies Reports Year End 2017 Results NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research
More informationSuccessful Prevention Strategies to Address the Opioid Crises
Successful Prevention Strategies to Address the Opioid Crises Shannon Breitzman, MSW, Principal Denver Office Lindsey Kato, MPH, CHES, Consultant Denver Office 1 LEARNING OBJECTIVES + Find out how to effectively
More informationBrighton and Sussex University Hospitals NHS Trust Board of Directors. Mark Smith Chief Operating Officer
Meeting: Brighton and Sussex University Hospitals NHS Trust Board of Directors Date: 24 th August 2015 Board Sponsor: Paper Author: Subject: Mark Smith Chief Operating Officer Clinical Director and Directorate
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationTitan Pharmaceuticals Overview
Corporate Presentation July 2014 1 Safe Harbor The presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
More informationMELISSA STAHL SENIOR RESEARCH MANAGER THE HEALTH MANAGEMENT ACADEMY
CASE STUDY MANAGING THE OPIOID EPIDEMIC: FAIRVIEW HEALTH SERVICES The Academy The Health Management Academy MELISSA STAHL SENIOR RESEARCH MANAGER THE HEALTH MANAGEMENT ACADEMY INTRODUCTION THE OPIOID EPIDEMIC
More informationInvestor presentation. Bioshares Biotech Summit July 2017
Investor presentation Bioshares Biotech Summit 2017 22 July 2017 1 Disclaimer Some of the information in this presentation may refer to Dimerix Limited ( Dimerix or the Company ) based on information available
More informationCTN Research Update. National Advisory Council on Drug Abuse May 8, Betty Tai, Ph.D. Center for the Clinical Trials Network
CTN Research Update National Advisory Council on Drug Abuse May 8, 2013 Betty Tai, Ph.D. Center for the Clinical Trials Network CTN Steering Committee NIDA - CCTN NIDA National Drug Abuse Treatment Clinical
More informationTaking Action Against Opioids through Research and Best Practice
Taking Action Against Opioids through Research and Best Practice Session 1002-7, March 6, 2018 Darshak Sanghavi, MD, Chief Medical Officer, OptumLabs Molly Jeffery, PhD, Scientific Director of Emergency
More informationMonitoring Protocol for Clozapine-induced Myocarditis. Copyright 2017, CAMH
1 Monitoring Protocol for Clozapine-induced Myocarditis 1 Agenda Problem Identification / Identification Importance / Importance Baseline Workflow Baseline Workflow Baseline Data Baseline Data Objectives
More informationAlthough PDMPs are separately managed and maintained by each state or jurisdiction, the national network facilitates more uniformity among states.
NASCSA Statement for the Record as presented by Barbara A Carter, President, NASCSA Submitted to: Department of Health and Human Services, Food and Drug Administration, Opioid Policy Steering Committee
More informationJerry Cochran, MSW, PhD University of Utah School of Medicine Department of Internal Medicine Department of Psychiatry
Jerry Cochran, MSW, PhD University of Utah School of Medicine Department of Internal Medicine Department of Psychiatry Acknowledgements Funding for this work has come from: The Staunton Farm Foundation
More informationepat Technologies Ltd Investor Presentation June 2017
epat Technologies Ltd Investor Presentation June 2017 1 Investment Highlights A digital healthcare company Mobile apps to assess and monitor pain pain the most common reason to see a doctor accurate pain
More informationTime Topic / Activity Presenter(s)
Social Innovation Fund Pre-Launch Training Agenda September 14, 2013 Time Topic / Activity Presenter(s) 8:00 REGISTRATION 8:30 Welcome - JAHF and AIMS Center Introductions 8:50 Agenda & Materials Review
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationTSX Venture: RVV OTCQB: RVVTF
TSX Venture: RVV OTCQB: RVVTF The image part with relationship ID rid3 was not found in the file. 2017 Annual General and Special Meeting of Shareholders December 19, 2017 Revive Therapeutics Ltd. Office:
More information8/16/2018. California s MAT Expansion Hub and Spoke System: Provider and Consumer Perspectives. Agenda. No Wrong Door
California s MAT Expansion Hub and Spoke System: Provider and Consumer Perspectives Gloria Miele, PhD, Learning Collaborative Coordinator, Hub and Spoke MAT Expansion Project Richard Rawson, PhD, Professor
More informationAI Cancer Detection. Using AI to detect cancer early
AI Cancer Detection Using AI to detect cancer early Peter Ma Hackathon Intel Software Innovator 5 startups Built AI, IoT, BlockChain, Mobile Problem Between 40 and 50 percent of Americans who live to age
More informationInnovator Case Studies: Oncology Networks
Innovator Case Studies: Oncology Networks J. Ike Nicoll Chief Executive Officer Cancer Clinics of Excellence Alan Armer, Ph.D. Vice President, Research & Development Catholic Health Initiatives Cancer
More informationAkouos launched in 2017 with funding from 5AM Ventures, NEA, and Partners Innovation Fund. Further information can be found at
Akouos to Build Premier Gene Therapy Company Focused on Hearing and Balance Disorders with Backing from Leading Life Science Investors and Strategic Licenses from Massachusetts Eye and Ear and Lonza Akouos
More information2/20/2019. Source: Source:
The misuse of and addiction to opioids including prescription pain relievers, heroin, and synthetic opioids such as fentanyl is a serious national crisis that affects public health as well as social and
More informationNEEDLE-FREE INJECTION SAFE. EASY. NO NEEDLE.
Stratis NEEDLE-FREE INJECTION SAFE. EASY. NO NEEDLE. COMPANY OVERVIEW Based in Golden, Colorado, PharmaJet s mission is worldwide acceptance of PharmaJet Needle- Free devices as a standard of care in the
More informationADDRESSING THE OPIOID EPIDEMIC. Joint principles of the following organizations representing front-line physicians
ADDRESSING THE OPIOID EPIDEMIC Joint principles of the following organizations representing front-line physicians American Academy of Family Physicians American Academy of Pediatrics American College of
More informationC O M P A N Y P U R P O S E
P I T C H D E C K C O M P A N Y P U R P O S E Evidence-Based Solution Using Virtual Reality, Artificial Intelligence, & Blockchain Technology for Pain Management, Prevention of Substance Use Disorders,
More informationQiG INS Conference May 22, 2011
Strategy & Vision Growth Electrochem Medical Device Evolution QiG Cardio vascular QiG INS Conference May 22, 2011 Greatbatch Medical Neuro modulation 1 GREATBATCH TODAY 2010 Revenue by Product Line NYSE:
More informationFinancial impact of opioids, alcohol, & street drugs
2018 Los Angeles State of Reform Health Policy Conference Financial impact of opioids, alcohol, & street drugs A COMMUNITY-BASED ORGANIZATION S PERSPECTIVE VITKA EISEN, MSW, ED.D. PRESIDENT & CEO, HEALTHRIGHT
More informationCanadian Association of Chiefs of Police. Drug Abuse Committee. Annual Report
Canadian Association of Chiefs of Police Drug Abuse Committee Annual Report Submitted by: Chief Mark Mander, Chair Message from the Chair: In November 2012, I was elected Chair of the committee and Eric
More informationFAMILY & CHILDREN S SERVICES STRATEGIC PLAN
2014-2019 FAMILY & CHILDREN S SERVICES STRATEGIC PLAN WHO WE ARE Family & Children s Services is a leading provider of behavioral health care and family services for people of all ages in Tulsa and surrounding
More informationParity: Innovation in Practice
Parity: Innovation in Practice Karen Turner Director of Mental Health 11 February 2016 Why does parity matter? 1:4 adults experience at least one diagnosable mental health problem a year 1:10 children
More informationThe Care Alliance for Opioid Dependence
The Care Alliance for Opioid Dependence The Vermont Hub and Spoke Model John Brooklyn, MD Clinical Assistant Professor of Family Practice and Psychiatry University of Vermont College of Medicine Medical
More informationTaking Action Against Opioids through Research and Best Practice
Taking Action Against Opioids through Research and Best Practice Session 7, March 6, 2018 Darshak Sanghavi, MD, Chief Medical Officer, OptumLabs Molly Jeffery, PhD, Scientific Director of Emergency Care
More informationManagement Options for Opioid Dependence:
Management Options for Opioid Dependence: Policy Implications and Recommendations Dan Ollendorf, PhD Sarah Jane Reed, MSc New England CEPAC Goal: To improve the application of evidence to guide practice
More informationMEDICATION ASSISTED ADDICTION TREATMENT: Appropriate Use
MEDICATION ASSISTED ADDICTION TREATMENT: Appropriate Use Louis E. Baxter, Sr., M.D., DFASAM Executive Medical Director-PAPNJ Assistant Clinical Professor Medicine Rutgers New Jersey Medical School DMHAS-Addiction
More informationRobert Brooke Chief Executive Officer
Robert Brooke Chief Executive Officer 2 Safe Harbor Statement Our commentary and responses to your questions may contain forward-looking statements, including comments concerning product development programs,
More informationPlanning Case Study. Barbara Ann Karmanos Cancer Institute McLaren Health Care Detroit, Michigan
Planning Case Study Barbara Ann Karmanos Cancer Institute McLaren Health Care Detroit, Michigan On the vanguard of thought. Reimagining The futurecancer of healthcare Care requires nothing less. Planning
More informationThe Prime Minister s Challenge on Dementia Lorraine Jackson Deputy Director: Dementia Policy Department of Health 12 April 2016
The Prime Minister s Challenge on Dementia 2020 1 Lorraine Jackson Deputy Director: Dementia Policy Department of Health 12 April 2016 Costs and impact of dementia Estimated 676,000 people in England with
More informationSmall Steps. Big Benefits. Improve population health and reduce costs by incentivizing members to make healthy choices
Small Steps Big Benefits Improve population health and reduce costs by incentivizing members to make healthy choices An ounce of prevention is worth a pound of cure. Ben Franklin Researchers have noted
More informationPosition Specification
Position Specification Empirical Spine, Inc. Title: Vice President, Clinical & Regulatory Affairs Opportunity: The Vice President, Clinical & Regulatory Affairs will play a key role in the success of this
More informationFor personal use only
AusCann Makes Major Progress Towards Production of Cannabinoid Medicines During FY18 Highlights Undertook comprehensive pharmaceutical development project to create an optimal dosage form cannabinoid medicine
More informationSBIRT in SBHCs: A Model for Adolescent Substance Use Prevention
SBIRT in SBHCs: A Model for Adolescent Substance Use Prevention Introduction Disturbingly, most adolescents don t see the use of marijuana, alcohol, illicit drugs, and tobacco as a risk. (SAMHSA, 2010)
More informationFor personal use only
13 February 2018 Creso reports strong progress with construction of its Canadian medicinal cannabis production facility in Nova Scotia Highlights: Site works at Creso s Canadian medicinal cannabis production
More informationCOMPANY PRESENTATION JULY Bob Bechard Executive Vice-President Corporate Development & Licensing
COMPANY PRESENTATION JULY 2018 Bob Bechard Executive Vice-President Corporate Development & Licensing Forward Looking Statements Some statements in this release may contain forward-looking information.
More informationThe PeriRx, LLC Executive Team
The PeriRx, LLC Executive Team Stephen M. Swanick / President, CEO and Founder Mr. Swanick is the President, Chief Executive Officer and Founder of PeriRx, LLC. PeriRx was formed by Mr. Swanick as a premier
More informationA world leading addiction treatment company with enormous future potential. Jefferies Conference, London 18 th November 2015
A world leading addiction treatment company with enormous future potential Jefferies Conference, London 18 th November 2015 Forward looking statements This presentation contains certain statements that
More informationPlanning Case Study. Barbara Ann Karmanos Cancer Institute McLaren Health Care Detroit, Michigan
Planning Case Study Barbara Ann Karmanos Cancer Institute McLaren Health Care Detroit, Michigan On the vanguard of thought. Reimagining The futurecancer of healthcare Care requires nothing less. Planning
More informationNATIONAL ACADEMIES OF SCIENCES ENGINEERING MEDICINE
NATIONAL ACADEMIES OF SCIENCES ENGINEERING MEDICINE THE HEALTH EFFECTS OF CANNABIS AND CANNABINOIDS: THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH ADDRESSING BARRIERS TO POLICY, SURVEILLANCE,
More informationMedication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs
Medication Assisted Treatment Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs Disclosures Employed by the Department of Veterans Affairs
More informationCAELUM BIOSCIENCES. Corporate Overview May, 2017
CAELUM BIOSCIENCES Corporate Overview May, 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning
More informationFor personal use only
Overview from the Chairman 2011 is not yet half way through and it is already by far the most productive in the 10 years since Brain Resource began. From our offices in Sydney and our new San Francisco
More informationJP Morgan Healthcare Conference
JP Morgan Healthcare Conference Lamberto Andreotti Chief Executive Officer January 14, 2014 Forward-Looking Information During this meeting, we will make statements about the Company s future plans and
More informationCOMPANY PRESENTATION. Bernard Fortier, CEO
COMPANY PRESENTATION Bernard Fortier, CEO Forward Looking Statements Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationSPECIALTY MEDICAL CANNABIS COMPANY
SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward
More informationTitan Pharmaceuticals: Highlights
Corporate Presentation January 2013 1 Safe Harbor The presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
More informationDeveloping Xanamem for Alzheimer s Dementia
Developing Xanamem for Alzheimer s Dementia Dr. Bill Ketelbey CEO, Actinogen Medical Investor Presentation March 2015 Forward Statements This presentation has been prepared by Actinogen Limited. ( Actinogen
More informationBetter Diagnostics for Life
NASDAQ: NMRD Better Diagnostics for Life Corporate Presentation November 2018 Forward-Looking Statement This presentation includes forward-looking statements that are subject to many risks and uncertainties.
More informationVifor Pharma Leading portfolio and mid-term growth drivers
Vifor Pharma Leading portfolio and mid-term growth drivers Stefan Schulze CEO VFMCRP Nominated President of the Corporate Executive Committee and COO of the Vifor Pharma Group Media Conference, 14 March
More informationRural Health Initiative
Rural Health Initiative 1 Our Vision For Rural Health To facilitate best in class health care in rural areas and reduce rural health care in Idaho as a disparity. To facilitate equity in health in rural
More informationFred Podesta, Department of Finance and Administrative Services Director Catherine Lester, Human Services Department Director
MEMORANDUM DATE: TO: VIA: FROM: Subject: Councilmember Teresa Mosqueda, Chair Housing, Health, Energy, and Workers Rights Ben Noble, Budget Director Fred Podesta, Department of Finance and Administrative
More information6 million pregnancies occur in the US each year. Nearly 3 million of these are unplanned.
6 million pregnancies occur in the US each year. Nearly 3 million of these are unplanned. Upstream USA is a nonprofit organization that helps health centers across the country eliminate barriers that prevent
More informationFor personal use only
ASX ANNOUNCEMENT 22 NOVEMBER 2017 AGM ADDRESSES FROM THE CHAIRMAN & CEO 22 November 2017 Cann Group Limited (ASX: CAN) is pleased to provide the following addresses to be delivered by its Chairman Allan
More informationMild Cognitive Impairment - Pipeline Review, H1 2017
Report Information More information from: https://www.wiseguyreports.com/reports/1184709-mild-cognitive-impairment-pipeline-review-h1-2017 Mild Cognitive Impairment - Pipeline Review, H1 2017 Report /
More informationHow to use GoToWebinar
How to use GoToWebinar RESEARCH & TRAINING CENTER FOR PATHWAYS TO POSITIVE FUTURES Move any electronic handheld devices away from your computer and speakers We recommend that you close all file sharing
More information